Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 1,300 | 200 | 1,800 | 2,192 | 7,231 |
| Gross Profit | 1,300 | 200 | 1,800 | 2,192 | 7,231 |
| Operating Expenses | 136,325 | 331,648 | 221,021 | 131,309 | 83,795 |
| Operating Income | -135,025 | -331,448 | -219,221 | -129,117 | -76,564 |
| Interest Expense | 12,196 | 13,491 | 31,840 | 18,181 | 5,216 |
| Other Income | 7,168 | 2,032,513 | 9,703 | 2,075 | 14 |
| Pre-tax Income | -140,053 | 1,687,574 | -241,358 | -145,223 | -81,766 |
| Income Tax | 2 | 2 | 3 | 3 | 2 |
| Net Income Continuous | -140,055 | 1,687,572 | -241,361 | -145,226 | -81,768 |
| Net Income | $-140,055 | $1,687,572 | $-241,361 | $-145,226 | $-81,768 |
| EPS Basic Total Ops | -9.04 | 114.01 | -5.12 | -3.62 | -2.15 |
| EPS Basic Continuous Ops | -9.04 | 114.01 | -5.12 | -3.62 | -2.15 |
| EPS Diluted Total Ops | -9.04 | 112.62 | -5.12 | -3.62 | -2.15 |
| EPS Diluted Continuous Ops | -9.04 | 112.62 | -5.12 | -3.62 | -2.15 |
| EPS Diluted Before Non-Recurring Items | -9.04 | 112.62 | -5.12 | -3.62 | -2.15 |
| EBITDA(a) | $-132,542 | $-329,163 | $-213,131 | $-124,444 | $-74,135 |